Deutsche Bank Upgrades Coupang to Buy, Strong Regulatory Resilience
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Should l Buy BNTX?
Source: CNBC
- Rating Upgrade: Deutsche Bank upgraded Coupang from hold to buy, citing the company's strong resilience against regulatory scrutiny, particularly after facing a record antitrust fine in June 2024, which has not diminished its market position.
- Biotech Outlook: Goldman Sachs upgraded BioNTech from neutral to buy, highlighting the company's strategic suite of oncology programs targeting a potential market exceeding $100 billion, with key data expected to unlock in 2026, positioning it for leadership in emerging product cycles.
- Market Challenges: Barclays downgraded HP from equal weight to underweight, noting that the company faces significant long-term challenges in both PCs and printing, which will likely keep the stock under pressure in 2026 despite its current inexpensive valuation and lack of catalysts.
- EV Market Positioning: Macquarie upgraded Nio from market perform to outperform, asserting that the company is well-positioned to navigate the current headwinds in the Chinese electric vehicle market, thereby maintaining its competitive edge.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BNTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BNTX
Wall Street analysts forecast BNTX stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 106.990
Low
113.00
Averages
143.17
High
181.00
Current: 106.990
Low
113.00
Averages
143.17
High
181.00
About BNTX
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioNTech SE Stock Downgraded by Leerink Partners
- Rating Downgrade Impact: Leerink Partners downgraded BioNTech SE (NASDAQ:BNTX) from Outperform to Market Perform with a price target of $113, reflecting a 24% stock rally from December's low of $92, which outpaced the 4% gain of the biotechnology sector.
- Long-Term Outlook Positive: Despite the downgrade, Leerink Partners remains optimistic about BioNTech's long-term prospects, particularly regarding the development of pumitamig, a VEGFA/PD-L1 bispecific antibody partnered with Bristol Myers Squibb, indicating the company's potential in oncology.
- Strong Financial Position: BioNTech holds $20.3 billion in cash, expected to support the development of its oncology pipeline, ensuring robust financial backing for future research and development initiatives.
- Management Changes: On January 28, BioNTech appointed Kylie Jimenez as Chief People Officer, aiming to drive the company's strategy to become a multi-product oncology firm by 2030, with Jimenez responsible for shaping and executing the people strategy.
See More
Moderna's Flu Vaccine Receives FDA Review Approval
- FDA Review Decision: The FDA's agreement to review Moderna's experimental mRNA flu vaccine reverses its earlier refusal, stunning Wall Street and the medical community, marking a significant advancement in vaccine development.
- Positive Market Reaction: Following the FDA review announcement, Moderna's shares rose over 6%, reflecting investor confidence in the company's future flu vaccine market potential and paving the way for its goal of breaking even by 2028.
- New Application Strategy: Moderna's revised regulatory approach seeks full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, addressing FDA criticisms of its trial design and enhancing the vaccine's market competitiveness.
- Changing Regulatory Environment: The FDA's decision highlights significant shifts in U.S. vaccine regulatory policies, particularly under the leadership of the new Secretary of Health and Human Services, with Moderna's application process facing stricter scrutiny, illustrating the complexities and challenges of vaccine regulation.
See More
BioNTech (BNTX.US) Executive Plans to Sell $93.87 Million in Common Stock via Form 144
Share Sale Announcement: Medine GmbH plans to sell 858.21K shares of its common stock in BioNTech (BNTX.US) on February 12, with a total market value of approximately $93.87 million.
Reduction in Holdings: Medine GmbH has reduced its shareholding in BioNTech by 255.92K shares since January 13, 2026, with a total value of around $29.03 million.
See More
Pfizer Shares Decline Despite Strong Earnings: Concerns for Wall Street.
- Earnings Performance: Pfizer reported fourth-quarter earnings that significantly exceeded Wall Street expectations.
- Market Reaction: Despite strong earnings, Pfizer's stock experienced a decline in premarket trading.
See More
Oncolytics Biotech Strengthens Leadership Amid Oncology Market Surge
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to advance the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients when combined with standard chemotherapy, tripling the historical response rate of 6-11%, demonstrating significant efficacy in this difficult-to-treat population.
- FDA Alignment Success: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this challenging therapeutic area, further solidifying its market position.
- Strategic Expansion: The company has also expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, aiming to accelerate clinical development across multiple indications and enhance overall R&D capabilities.
See More
Oncolytics Biotech Strengthens Leadership to Advance Clinical Programs
- Leadership Enhancement: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to advance the company's registration-directed programs in gastrointestinal cancers.
- Breakthrough Efficacy Data: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients when combined with standard chemotherapy, significantly surpassing the historical 6-11% response rate, indicating its potential in difficult-to-treat patient populations.
- FDA Designation Approval: Oncolytics secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the initiation of the only immunotherapy registration trial planned for this challenging area, further solidifying its market position.
- Advisory Board Expansion: The company has expanded its Scientific Advisory Board by adding globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, laying the groundwork for accelerated clinical development across multiple indications.
See More
BioNTech SE Stock Downgraded by Leerink Partners
- Rating Downgrade Impact: Leerink Partners downgraded BioNTech SE (NASDAQ:BNTX) from Outperform to Market Perform with a price target of $113, reflecting a 24% stock rally from December's low of $92, which outpaced the 4% gain of the biotechnology sector.
- Long-Term Outlook Positive: Despite the downgrade, Leerink Partners remains optimistic about BioNTech's long-term prospects, particularly regarding the development of pumitamig, a VEGFA/PD-L1 bispecific antibody partnered with Bristol Myers Squibb, indicating the company's potential in oncology.
- Strong Financial Position: BioNTech holds $20.3 billion in cash, expected to support the development of its oncology pipeline, ensuring robust financial backing for future research and development initiatives.
- Management Changes: On January 28, BioNTech appointed Kylie Jimenez as Chief People Officer, aiming to drive the company's strategy to become a multi-product oncology firm by 2030, with Jimenez responsible for shaping and executing the people strategy.
See More
Moderna's Flu Vaccine Receives FDA Review Approval
- FDA Review Decision: The FDA's agreement to review Moderna's experimental mRNA flu vaccine reverses its earlier refusal, stunning Wall Street and the medical community, marking a significant advancement in vaccine development.
- Positive Market Reaction: Following the FDA review announcement, Moderna's shares rose over 6%, reflecting investor confidence in the company's future flu vaccine market potential and paving the way for its goal of breaking even by 2028.
- New Application Strategy: Moderna's revised regulatory approach seeks full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, addressing FDA criticisms of its trial design and enhancing the vaccine's market competitiveness.
- Changing Regulatory Environment: The FDA's decision highlights significant shifts in U.S. vaccine regulatory policies, particularly under the leadership of the new Secretary of Health and Human Services, with Moderna's application process facing stricter scrutiny, illustrating the complexities and challenges of vaccine regulation.
See More
BioNTech (BNTX.US) Executive Plans to Sell $93.87 Million in Common Stock via Form 144
Share Sale Announcement: Medine GmbH plans to sell 858.21K shares of its common stock in BioNTech (BNTX.US) on February 12, with a total market value of approximately $93.87 million.
Reduction in Holdings: Medine GmbH has reduced its shareholding in BioNTech by 255.92K shares since January 13, 2026, with a total value of around $29.03 million.
See More
Pfizer Shares Decline Despite Strong Earnings: Concerns for Wall Street.
- Earnings Performance: Pfizer reported fourth-quarter earnings that significantly exceeded Wall Street expectations.
- Market Reaction: Despite strong earnings, Pfizer's stock experienced a decline in premarket trading.
See More
Oncolytics Biotech Strengthens Leadership Amid Oncology Market Surge
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to advance the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients when combined with standard chemotherapy, tripling the historical response rate of 6-11%, demonstrating significant efficacy in this difficult-to-treat population.
- FDA Alignment Success: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this challenging therapeutic area, further solidifying its market position.
- Strategic Expansion: The company has also expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, aiming to accelerate clinical development across multiple indications and enhance overall R&D capabilities.
See More
Oncolytics Biotech Strengthens Leadership to Advance Clinical Programs
- Leadership Enhancement: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to advance the company's registration-directed programs in gastrointestinal cancers.
- Breakthrough Efficacy Data: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients when combined with standard chemotherapy, significantly surpassing the historical 6-11% response rate, indicating its potential in difficult-to-treat patient populations.
- FDA Designation Approval: Oncolytics secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the initiation of the only immunotherapy registration trial planned for this challenging area, further solidifying its market position.
- Advisory Board Expansion: The company has expanded its Scientific Advisory Board by adding globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, laying the groundwork for accelerated clinical development across multiple indications.
See More
